No Evidence for Ceftobiprole-Induced Immune Hemolytic Anemia in Three Phase 3 Clinical Trials.
Kamal A HamedTatiana WiktorowiczMaziar Assadi GehrPublished in: Infection and drug resistance (2020)
No evidence of hemolytic anemia associated with ceftobiprole was observed in either adults or children across several indications in this analysis of three large Phase 3 trials.